Cardiovascular

?
  • Created by: AJ-A
  • Created on: 10-05-22 08:40
If ectopic beats are spontaneous and the patient has a normal heart how do we treat it?
treatment is rarely required and reassurance to the patient will often suffice. If they are particularly troublesome, beta-blockers are sometimes effective
1 of 103
Atrial fibrillation can be managed by
either controlling the ventricular rate (‘rate control’) or by attempting to restore and maintain sinus rhythm (‘rhythm control’)
2 of 103
How to treat all patients with life-threatening haemodynamic instability caused by new-onset atrial fibrillation
emergency electrical cardioversion
3 of 103
How to treat patients presenting acutely but without life-threatening haemodynamic instability
if onset of arrhythmia is less than 48 hours, rate or rhythm control can be offered.
If rhythm control; can use electrical or pharmacological cardioversion (flecainide [if no structural/ischaemic heart disease] or amiodarone (if evidence of IHD)
4 of 103
How to treat pts presenting acutely when symptoms last >48hrs or unsure
Rate control is preferred by giving IV B-blocker (sotalol) and rate-limiting CCB such as verapamil (if LVEF > 40%)
if rhythm control is chosen; electrical cardioversion is preferred
5 of 103
If treating new-onset AF pts with pharmacological cardioversion which drugs should be used
Flecainide acetate (if no structural or ischaemic heart disease present)
or
Amiodarone hydrochloride
6 of 103
If atrial fibrillation has been present for more than 48 hours and rhythm control is the chosen option, electrical cardioversion is preferred to pharmacological cardioversion but what must happen first
patient must be fully anticoagulated for at least 3 weeks, If this is not possible, a left atrial thrombus should be ruled out and parenteral anticoagulation (heparin) commenced immediately before cardioversion and 4 weeks oral anticoag given after
7 of 103
Rate control is the preferred first-line treatment strategy for atrial fibrillation except...
in new-onset atrial fibrillation,
pts with atrial flutter suitable for an ablation strategy,
pts with atrial fibrillation with a reversible cause, pts with heart failure primarily caused by atrial fibrillation or if rhythm control is more suitable
8 of 103
Rate control is the preferred first-line treatment strategy for atrial fibrillation using
a standard beta-blocker (not sotalol hydrochloride), or with a rate-limiting calcium channel blocker such as diltiazem hydrochloride [unlicensed indication] or verapamil hydrochloride as monotherapy
9 of 103
Digoxin monotherapy should only be considered for...
initial rate control in patients with non-paroxysmal atrial fibrillation who are predominantly sedentary, or in those where other rate-limiting drugs are unsuitable
10 of 103
When monotherapy fails to adequately control the ventricular rate, consider combination therapy with any 2 of...
a beta-blocker, digoxin, diltiazem hydrochloride.
If ventricular function is diminished (LVEF <40%), the combination of a beta-blocker (that is licensed for use in heart failure) and digoxin is preferred.
. Digoxin is also used when atrial fibrillation i
11 of 103
flecainide acetate and propafenone hydrochloride should be avoided in patients with
known ischaemic or structural heart disease
12 of 103
when should digoxin monotherapy be considered
it should be considered for initial rate control therapy for pts with non-paroxysmal AF and when other rate-limiting drugs are unsuitable.

If ventricular function is diminished (LVEF <40%), the combination of a beta-blocker (that is licensed for use in h
13 of 103
If drug treatment is required to maintain sinus rhythm (‘rhythm control’) post-cardioversion use:
standard beta-blocker (not sotalol hydrochloride) as first-line treatment
Dronedarone may be considered as a second-line treatment option in patients with persistent or paroxysmal atrial fibrillation
14 of 103
patients with new-onset atrial fibrillation who are receiving subtherapeutic or no anticoagulation therapy should be given:
Parenteral anticoagulation (heparin)
15 of 103
direct-acting oral anticoagulant include
apixaban, dabigatran etexilate, edoxaban, or rivaroxaban
16 of 103
Can aspirin be used as monotherapy in AF stroke prevention
aspirin monotherapy solely for stroke prevention in patients with atrial fibrillation is not recommended.
17 of 103
what is the treatment of choice If rapid conversion to sinus rhythm is necessary
Direct current cardioversion is usually the treatment of choice
18 of 103
intravenous adenosine should be given to treat
paroxysmal supraventricula tachycardia
19 of 103
If adenosine is ineffective or contra-indicated in Paroxysmal supraventricular tachycardia
give:
intravenous verapamil hydrochloride as an alternative, but it should be avoided in patients recently treated with beta-blockers.
20 of 103
how to prevent Recurrent episodes of paroxysmal supraventricular tachycardia with medication?
diltiazem hydrochloride, verapamil hydrochloride, beta-blockers including sotalol hydrochloride, flecainide acetate or propafenone hydrochloride.
21 of 103
In arrhythmia after a MI Bradycardia, particularly if complicated by hypotension, should be treated with
intravenous dose of atropine sulfate the dose may be repeated if necessary. If there is a risk of asystole, or if the patient is unstable and has failed to respond to atropine sulfate, adrenaline/epinephrine should be given by intravenous infusion
22 of 103
Pulseless ventricular tachycardia or ventricular fibrillation require
Resuscitation
23 of 103
Patients with unstable sustained ventricular tachycardia, who continue to deteriorate with signs of hypotension or reduced cardiac output, should receive
direct current cardioversion to restore sinus rhythm
If this fails, intravenous amiodarone hydrochloride should be administered and direct current cardioversion repeated
24 of 103
Patients with sustained ventricular tachycardia who are haemodynamically stable can be treated with
intravenous anti-arrhythmic drugs
Amiodarone hydrochloride is the preferred drug. Flecainide acetate, propafenone hydrochloride, and, although less effective, lidocaine hydrochloride have all been used
25 of 103
Non-sustained ventricular tachycardia can be treated with
A Beta Blocker
26 of 103
Torsade de pointes is a form of
ventricular tachycardia associated with a long QT syndrome
27 of 103
Episodes are usually self-limiting, but are frequently recurrent and can cause impairment or loss of consciousness. If not controlled, the arrhythmia can progress to ventricular fibrillation and sometimes death so how do we treat this?
Intravenous infusion of magnesium sulfate is usually effective. A beta-blocker (but not sotalol hydrochloride) and atrial (or ventricular) pacing can be considered.
Anti-arrhythmics can further prolong the QT interval, thus worsening the condition
28 of 103
Anti-arrhythmic drugs can be classified clinically into
those that act on supraventricular arrhythmias e.g. verapamil hydrochloride),
those that act on both supraventricular and ventricular arrhythmias (e.g. amiodarone hydrochloride),
those that act on ventricular arrhythmias (e.g. lidocaine hydrochloride)
29 of 103
Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity (the Vaughan Williams classification)
Class I: membrane stabilising drugs (e.g. lidocaine, flecainide)
Class II: beta-blockers
Class III: amiodarone; sotalol (also Class II)
Class IV: calcium-channel blockers (includes verapamil but not dihydropyridines)
30 of 103
Effect of hypokalemia on anti-arrhythmic drugs
hypokalaemia enhances the arrhythmogenic (pro-arrhythmic) effect of many drugs
31 of 103
what is the drug of choice for terminating paroxysmal supraventricular tachycardia
Adenosine
Verapamil hydrochloride may be preferable to adenosine in asthma.
32 of 103
What IV b blockers can be used in supraventricular arrhythmias
Intravenous administration of a beta-blocker such as esmolol hydrochloride or propranolol hydrochloride, can achieve rapid control of the ventricular rate
33 of 103
Drugs for both supraventricular and ventricular arrhythmias include
amiodarone hydrochloride, beta-blockers, disopyramide, flecainide acetate, procainamide and propafenone hydrochloride
34 of 103
Amiodarone hydrochloride is used in the treatment of arrhythmias, particularly when other drugs are ineffective or contraindicated. It can be used for
paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, and ventricular fibrillation. It can also be used for tachyarrhythmias associated with Wolff-Parkinson-White syndrome. It should be initiated only under hosp
35 of 103
when is IV disopyramide usually given
Disopyramide can be given by intravenous injection to control arrhythmias after myocardial infarction (including those not responding to lidocaine hydrochloride),
36 of 103
When is flecainide used
Flecainide acetate belongs to the same general class as lidocaine hydrochloride and may be of value for serious symptomatic ventricular arrhythmias. It may also be indicated for junctional re-entry tachycardias and for paroxysmal atrial fibrillation
37 of 103
when is propafenone used
Propafenone hydrochloride is used for the prophylaxis and treatment of ventricular arrhythmias and also for some supraventricular arrhythmias
38 of 103
What must one be cautioned of
weak beta-blocking activity (therefore caution is needed in obstructive airways disease—contra-indicated if severe
39 of 103
Drugs for supraventricular arrhythmias include
adenosine, cardiac glycosides, and verapamil hydrochloride.
40 of 103
Drugs for ventricular arrhythmias include
lidocaine hydrochloride.
41 of 103
What can be used for the treatment of ventricular tachycardia in haemodynamically stable patients, and ventricular fibrillation and pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation
Intravenous lidocaine hydrochloride
it is no longer the anti-arrhythmic drug of first choice
42 of 103
Drugs for both supraventricular and ventricular arrhythmias include
amiodarone hydrochloride, beta-blockers, disopyramide, flecainide acetate, procainamide (available from ‘special- order’ manufacturers or specialist importing companies), and propafenone hydrochloride.
Mexiletine can be used for the treatment of life-thre
43 of 103
Venous Thromboembolism consists of
deep-vein thrombosis (DVT) and pulmonary embolism (PE)
44 of 103
Symptoms of a DVT include
unilateral localised pain, swelling, tenderness, skin changes, and/or vein distension
45 of 103
Symptoms of a PE
chest pain, shortness of breath, and/or haemoptysis
46 of 103
There are two methods of thromboprophylaxis
mechanical and pharmacological. Options for mechanical prophylaxis are anti-embolism stockings that provide graduated compression and produce a calf pressure of 14–15 mmHg
Patients with risk factors for bleeding should only receive pharmacological prophyl
47 of 103
signs of haemodynamic instability
include pallor, tachycardia, hypotension, shock, and collapse
48 of 103
for patients with a confirmed proximal DVT or PE offer
either apixaban or rivaroxaban
49 of 103
If apixaban or rivaroxaban are unsuitable for proximal DVT or PE, offer either
low molecular weight heparin (LMWH) for at least 5 days followed by dabigatran etexilate or edoxaban; or
LMWH given concurrently with a vitamin K antagonist for at least 5 days or until the INR is at least 2.0 for 2 consecutive readings, followed by a vit
50 of 103
For renally impaired patients (estimated creatinine clearance between 15–50 ml/min) with a confirmed proximal DVT or PE
offer; Apixaban; Rivaroxaban;
LMWH for at least 5 days followed by either dabigatran etexilate (if estimated creatinine clearance is 30 ml/min or above) or edoxaban;
LMWH or heparin (unfractionated), given concurrently with a vitamin K antagonist for at l
51 of 103
Patients with a confirmed proximal DVT or PE should be offered anticoagulation treatment for
at least 3 months (3 to 6 months for those with active cancer
52 of 103
if rapid reversal of the effects of the heparin is required
protamine sulfate is a specific antidote (but only partially reverses the effects of low molecular weight heparins)
53 of 103
Patients suspected of having a transient ischaemic attack should immediately receive
aspirin.
54 of 103
Following a transient ischaemic attack or an ischaemic stroke (not associated with atrial fibrillation), long-term treatment with
clopidogrel [unlicensed in transient ischaemic attack] is recommended
if contra-indicated or not tolerated, patients can receive modified-release dipyridamole in combination with aspirin;
55 of 103
If starting or changing diuretic treatment for hypertension, offer
thiazide-like diuretic such as indapamide in preference to conventional thiazide diuretics, for example bendroflumethiazide or hydrochlorothiazide.
56 of 103
In type 1 diabetes, aim for a clinic blood pressure of
135/85 mmHg
57 of 103
Stage 1hypertension is a clinic blood pressure of
between 140/90 mmHg and 160/100 mmHg, and ambulatory daytime average or home blood pressure average of 135/85 mmHg or higher
58 of 103
Stage 2hypertension is a clinic blood pressure of
160/100 mmHg and 180/120 mmHg, and ambulatory daytime average or home blood pressure average of 150/95 mmHg or higher
Treat all patients who have stage 2 hypertension, regardless of age.
59 of 103
Severe hypertension is a clinic systolic blood pressure of
180 mmHg or higher, or a clinic diastolic blood pressure of 120 mmHg or higher.
60 of 103
target clinic blood pressure for patients aged under 80 years
below 140/90 mmHg

Ambp 135/85 mmHg
61 of 103
target clinic blood pressure for patients aged over 80 years
below 150/90 mmHg

Ambp 145/85 mmHg
62 of 103
symptoms of HF
shortness of breath, persistent coughing or wheezing, ankle swelling, reduced exercise tolerance, and fatigue
63 of 103
Which medications should be avoided in patients who have heart failure with reduced ejection fraction as these drugs reduce cardiac contractility
Rate-limiting calcium-channel blockers (verapamil hydrochloride, and diltiazem hydrochloride) and short-acting dihydropyridines (e.g. nifedipine, or nicardipine hydrochloride)
Patients with heart failure and angina may safely be treated with amlodipine.
64 of 103
Thiazide diuretics may only be of benefit in patients with
mild fluid retention and an eGFR greater than 30 mL/minute/1.73 m2.
65 of 103
first-line treatment for HF
An angiotensin-converting enzyme (ACE) inhibitor (e.g. perindopril, ramipril, captopril, enalapril maleate, lisinopril, quinapril or fosinopril sodium) and a beta-blocker licensed for heart failure (e.g. bisoprolol fumarate, carvedilol, or nebivolol) shou
66 of 103
Which Diuretics are recommended for the relief of breathlessness and oedema in patients with fluid retention
Loop diuretics such as furosemide, bumetanide, or torasemide are usually the diuretics of choice
67 of 103
a beta-blocker should not be withheld in the treatment of HF because of
age or the presence of diabetes, chronic obstructive pulmonary disease, peripheral vascular disease, erectile dysfunction, or interstitial pulmonary disease
68 of 103
What ARB's are licensed for heart failure
candesartan cilexetil, losartan potassium, or valsartan)
69 of 103
If heart failure symptoms persist or worsen despite optimal first-line treatment what should be given?
an aldosterone antagonist such as spironolactone or eplerenone should be offered as add-on therapy unless contraindicated (e.g. due to hyperkalaemia or renal impairment).
Hydralazine hydrochloride with a nitrate can be considered in patients who are intol
70 of 103
When initiating beta blockers what should be assessed at the start of treatment and after each dose change
heart rate, blood pressure and symptom control
71 of 103
How to manage HF In patients with chronic kidney disease
lower doses and slower dose titrations of ACE inhibitors, ARBs, aldosterone antagonists and digoxin should be considered
72 of 103
first choice for treating hypercholesterolaemia and moderate hypertriglyceridaemia
Statins
73 of 103
Severe hypercholesterolaemia or hypertriglyceridaemia not adequately controlled with a maximal dose of a statin may require the use of an additional lipid-regulating drug such as
ezetimibe
74 of 103
Although statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration, they are less effective than fibrates in reducing...
triglyceride concentration
75 of 103
what may be added to statin therapy if triglycerides remain high even after the LDL-cholesterol concentration has been reduced
fenofibrate
76 of 103
A high-intensity statin is defined as
the dose at which a reduction in LDL-cholesterol of greater than 40% is achieved.
The dose of the statin should be titrated to achieve a reduction in LDL-cholesterol concentration of greater than 50% from baseline.
77 of 103
Patients who have contra-indications to, or are intolerant of statins, can be considered for treatment with ______ as monotherapy
ezetimibe
78 of 103
A combination of a statin and ezetimibe is recommended if
if the maximum tolerated dose of a statin alone fails to provide adequate control of LDL-cholesterol, or a switch to an alternative statin is being considered
79 of 103
in patients for whom statins or ezetimibe are inappropriate Treatment with _________ or ________ can be considered under specialist advice
a fibrate or a bile acid sequestrant (such as colestyramine or colestipol hydrochloride)
80 of 103
The combination of a statin with a fibrate carries an increased risk of
muscle-related side-effects (including rhabdomyolysis)
gemfibrozil with a statin increases the risk of rhabdomyolysis considerably—this combination should not be used.
81 of 103
MABs that can be used to lower lipids
alirocumab and evorocumab
82 of 103
why is high-dose (80 mg) simvastatin not recommended
there is an increased risk of myopathy
83 of 103
Drugs used for high intensity lipid reduction
Atorvastatin (20,40,80mg) and Rosuvastatin (10,20,40mg)

Simvastating 80mg is not recommended due to myopathy risks
84 of 103
Drugs used in low intensity (first line) lipid modification
Pravastatin (10,20,40mg), Fluvastatin (20,40mg) and Simvastatin (10mg)
85 of 103
Drugs used in medium intensity lipid modification
Fluvastatin (80mg), Simvastatin (20,40mg), Rosuvastatin(5mg), Atorvastatin(10mg)
86 of 103
Secondary causes of dyslipidaemia to be addressed before starting statins
hypothyroidism, uncontrolled diabetes, liver disease and kidney damage
87 of 103
Cuation of statins in diabetes
Can raise HBA1c
88 of 103
Interactions with statins that increase statin levels (increasing risk of myopathy)
Amiodarone, grapefruit juice, CCB's, antifungals (itraconazole, ciclosporin)
89 of 103
If prescribed statin with macrolide antibiotic e.g. clarithomycin
stop taking statin until antibiotic course is finished
90 of 103
If prescribed statin with fusidic acid
Restart statin 7 days after last fusidic acid dose
91 of 103
Statins in pregnancy and breast feeding
AVOID
92 of 103
Bile acid sequestrants interactions
Impairs absorption of fat soluble vitamins ADEK and other drugs so take other drugs 1 hour before except Colesevelam take 4 hours before
or
take bile acid sequestrant 4 hours after other drugs
93 of 103
first-line therapy for long-term prevention of chest pain in patients with stable angina
a beta-blocker (such as atenolol, bisoprolol fumarate, metoprolol tartrate or propranolol hydrochloride)
If a beta-blocker alone fails to control symptoms adequately, a combination of a beta-blocker and a calcium-channel blocker should be considered
94 of 103
an alternative if beta-blockers are contra-indicated in prevention of stable angina
A rate-limiting calcium-channel blocker (such as verapamil hydrochloride or diltiazem hydrochloride)
95 of 103
A long-acting nitrate, ivabradine, nicorandil, or ranolazine, should also be considered in addition or as monotherapy to the treatment of stable angina when?
If combination is not appropriate due to intolerance of, or contra-indication to, either beta-blockers or calcium-channel blockers or as monotherapy in patients who cannot tolerate/CI/inadequate response to beta-blockers and calcium-channel blockers
96 of 103
In stable angina response to treatment should be assessed every...
2–4 weeks
97 of 103
All patients with stable angina due to atherosclerotic disease should be given long-term treatment with...
low-dose aspirin and a statin
98 of 103
if the patient has diabetes with stable angina which drug is recommended
Treatment with an ACE inhibitor should be considered
99 of 103
ACS initial management
Pain relief should be offered as soon as possible with glyceryl trinitrate (sublingual or buccal). Intravenous opioids such as morphine may also be administered.
A loading dose of aspirin should be given as soon as possible
100 of 103
most patients with a STEMI should be offered a second antiplatelet agent in addition to aspirin such as
prasugrel, ticagrelor, or clopidogrel
101 of 103
In STEMI and NSTEMI For secondary prevention, patients should be offered treatment with
angiotensin-converting enzyme (ACE) inhibitor, a beta-blocker, dual antiplatelet therapy and a statin
If intolerant to an ACE inhibitor, an angiotensin II receptor blocker (ARB) should be offered instead.
102 of 103
In secondary prevention of ACS Treatment with aspirin should continue indefinitely. Dual antiplatelet therapy (aspirin with a second antiplatelet) should be continued for up to
12 months unless contraindicated
103 of 103

Other cards in this set

Card 2

Front

Atrial fibrillation can be managed by

Back

either controlling the ventricular rate (‘rate control’) or by attempting to restore and maintain sinus rhythm (‘rhythm control’)

Card 3

Front

How to treat all patients with life-threatening haemodynamic instability caused by new-onset atrial fibrillation

Back

Preview of the front of card 3

Card 4

Front

How to treat patients presenting acutely but without life-threatening haemodynamic instability

Back

Preview of the front of card 4

Card 5

Front

How to treat pts presenting acutely when symptoms last >48hrs or unsure

Back

Preview of the front of card 5
View more cards

Comments

No comments have yet been made

Similar Medicine resources:

See all Medicine resources »See all Medicine resources »